文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

18F-NaF PET/CT 预测卡博替尼联合免疫治疗晚期泌尿系统肿瘤患者的总生存期

18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-14

研究前瞻性纳入接受卡博替尼联合纳武利尤单抗(±伊匹木单抗)治疗的晚期泌尿系统肿瘤患者,于治疗前和治疗后8周行18F-NaF PET/CT,以SUV阈值10测量氟亲和骨总体积(FTV)。30例基线有骨转移患者中,基线总病灶氟摄取(TLF)较高者总生存期较短(3.4 vs 14个月,p=0.022),随访时SUVmax较高者总生存期较短(5.6 vs 24个月,p=0.010)。

要点

  • 基线TLF较高与总生存期较短相关(3.4 vs 14个月,p=0.022)。
  • 随访时SUVmax较高与总生存期较短相关(5.6 vs 24个月,p=0.010)。
  • 治疗后FTV、TLF及其百分比变化与总生存期无显著相关。

核心结论

  • 基线TLF较高和随访时SUVmax较高的泌尿系统肿瘤骨转移患者,接受卡博替尼联合纳武利尤单抗(±伊匹木单抗)治疗后总生存期较短。
  • 18F-NaF PET/CT可能有助于预测该人群的总生存期。

研究设计与样本

  • 前瞻性I期临床试验,招募晚期泌尿系统肿瘤患者接受卡博替尼联合纳武利尤单抗(±伊匹木单抗)治疗。
  • 治疗前和治疗后8周行18F-NaF PET/CT,以SUV阈值10测量FTV。
  • 共111例患者行NaF PET/CT,其中30例基线有骨转移。

主要发现

  • 30例骨转移患者总生存期0.23–34个月(中位6.0个月),研究期间4例存活。
  • 基线FTV范围9.6–1570 ml(中位439 ml);治疗后8周19例可评估患者FTV范围56–6296 ml(中位448 ml)。
  • 基线TLF较高者总生存期短于较低者(3.4 vs 14个月;p=0.022)。
  • 随访时SUVmax较高者总生存期短于较低者(5.6 vs 24个月;p=0.010)。
  • 治疗后8周FTV和TLF组间无显著差异(5.6 vs 17个月;p=0.49),FTV百分比变化(12 vs 14个月;p=0.49)和TLF百分比变化(5.6 vs 17个月;p=0.54)亦无显著差异。

关键数值与推荐

  • 以SUV阈值10定义氟亲和骨体积(FTV)。
  • 基线TLF较高组与较低组总生存期分别为3.4个月和14个月(p=0.022)。
  • 随访时SUVmax较高组与较低组总生存期分别为5.6个月和24个月(p=0.010)。

临床怎么用

  • 对接受卡博替尼联合免疫治疗的晚期泌尿系统肿瘤骨转移患者,可考虑基线18F-NaF PET/CT测量TLF及随访SUVmax以辅助预后评估。
  • 治疗后8周FTV、TLF及其百分比变化在本研究中未显示与总生存期显著相关,解读时需谨慎。

局限性

  • 骨转移亚组样本量较小(30例基线骨转移,19例有治疗后8周FTV数据)。
  • 研究期间仅4例骨转移患者存活,生存分析事件数有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the prognostic value of 18F-sodium fluoride (NaF) PET/CT in patients with urological malignancies treated with cabozantinib and nivolumab with or without ipilimumab. METHODS: We prospectively recruited patients with advanced urological malignancies into a phase I trial of cabozantinib plus nivolumab with or without ipilimumab. NaF PET/CT scans were performed pre- and 8 weeks post-treatment. We measured the total volume of fluoride avid bone (FTV) using a standardized uptake value (SUV) threshold of 10. We used Kaplan-Meier analysis to predict the overall survival (OS) of patients in terms of SUVmax, FTV, total lesion fluoride (TLF) uptake at baseline and 8 weeks post-treatment, and percent change in FTV and TLF. RESULT: Of 111 patients who underwent NaF PET/CT, 30 had bone metastases at baseline. Four of the 30 patients survived for the duration of the study period. OS ranged from 0.23 to 34 months (m) (median 6.0 m). The baseline FTV of all 30 patients ranged from 9.6 to 1570 ml (median 439 ml). The FTV 8 weeks post-treatment was 56-6296 ml (median 448 ml) from 19 available patients. Patients with higher TLF at baseline had shorter OS than patients with lower TLF (3.4 vs 14 m; p = 0.022). Patients with higher SUVmax at follow-up had shorter OS than patients with lower SUVmax (5.6 vs 24 m; p = 0.010). However, FTV and TLF 8 weeks post-treatment did not show a significant difference between groups (5.6 vs 17 m; p = 0.49), and the percent changes in FTV (12 vs 14 m; p = 0.49) and TLF (5.6 vs 17 m; p = 0.54) also were not significant. CONCLUSION: Higher TLF at baseline and higher SUVmax at follow-up NaF PET/CT corresponded with shorter survival in patients with bone metastases from urological malignancies who underwent treatment. NaF PET/CT may be a useful predictor of OS in this population.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lim I, Lindenberg ML, Mena E, et al. 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. Eur J Nucl Med Mol Imaging. 2019. PMID: 31522271. doi:10.1007/s00259-019-04483-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。